P21: Scientific Profile

Publicado el 12 de julio de 2026

P21 (P021, synonym Ac-DGGLAG-NH2) is an acetylated and amidated hexapeptide derived from the biologically active region of ciliary neurotrophic factor (CNTF), studied for research as a neurogenic and neurotrophic agent. In preclinical models it acts by mimicking the trophic signaling of CNTF and modulating pathways associated with tau phosphorylation. Product intended exclusively for research use.

P21, also identified by its development code P021 and by the structural synonym Ac-DGGLAG-NH2, is a small hexapeptide derived from the biologically active region of ciliary neurotrophic factor (CNTF). Its sequence corresponds to Ac-Asp-Gly-Gly-Leu-Ala-Gly-NH2, that is, a core of six residues (Asp-Gly-Gly-Leu-Ala-Gly) with the N-terminus acetylated and the C-terminus amidated. Its molecular formula is C21H35N7O9 and its molecular weight is approximately 529.55 g/mol. It is classified within the category of low-molecular-weight nootropic and neurotrophic compounds. Unlike full neurotrophic proteins, P21 was designed as a compact peptidomimetic with the aim of retaining part of the trophic activity of the larger parent molecule in a format more manageable for experimental work. Because it lacks a unique assigned CAS number and is often presented as synthetic laboratory material, it should be treated as a synthetic peptide compound intended solely for research.

The origin of P21 lies in the line of work on CNTF-derived neurotrophic peptides developed by the group of Khalid Iqbal and Inge Grundke-Iqbal. The strategy consisted of identifying the peptide fragment responsible for the neurogenic activity of CNTF and optimizing it to reduce molecular size and the unfavorable properties associated with the full cytokine. From that line derive compounds such as the one called Peptide 6 and, subsequently, P021 as a version with terminal modifications (acetylation and amidation) aimed at improving stability against exopeptidases and pharmacokinetic properties in animal models. It is important to emphasize that virtually all of the characterization of P21 comes from preclinical studies —cell cultures and rodent models— and that much of this body of evidence comes from a small number of research groups. Clinical evidence is still nonexistent and its profile remains in the preclinical phase, so any claim about clinical applications would be premature.

From a structural standpoint, P21 is a short, amphoteric linear peptide: the aspartate residue provides negative charge, while leucine and alanine contribute a partially hydrophobic character. N-terminal acetylation and C-terminal amidation eliminate the charges of the ends, which usually translates into greater resistance to enzymatic degradation and a diffusion profile different from that of the unprotected peptide. These modifications are characteristic of peptidomimetics designed to improve in vitro half-life and exposure in in vivo models.

Regarding the mechanism of action proposed in the preclinical literature, P21 is described as a partial functional agonist of the trophic signaling associated with CNTF, capable of reproducing neurogenic effects without fully activating the cascades responsible for the adverse effects attributed to the intact cytokine. In experimental models, P21 has been reported to promote neurogenesis in the dentate gyrus of the hippocampus, to increase markers of synaptic plasticity, and to raise the expression of neurotrophic factors such as BDNF. Additionally, various preclinical studies have explored its capacity to reduce hyperphosphorylation of the tau protein, a phenomenon associated with the dysregulation of kinases such as GSK-3β and with neurofibrillary-type pathology in animal models of neurodegeneration. These effects have been linked both to the promotion of maturation and survival of adult-born neurons and to the restoration of synaptic density in paradigms of injury or aging. It is worth noting that these mechanisms describe observations in experimental systems and do not constitute therapeutic indications.

The documented research applications for P21 concentrate on experimental neuroscience. It has been used as a tool to study adult neurogenesis, hippocampal plasticity, and learning and memory in rodent models, as well as in preclinical models of Alzheimer's disease, Down syndrome, and other contexts of age-related cognitive decline. In these designs, research groups have evaluated outcomes such as performance in spatial memory tests, dendritic spine density, phosphorylated tau burden, and the expression of trophic factors. It has also served as a probe to explore the relationship between neurotrophic signaling and tau pathology. All of these applications correspond to a laboratory context and should not be interpreted as validated uses outside of research.

Regarding the level of evidence, P21 should be considered a compound with a preclinical profile that is relatively poorly characterized independently. There is a set of studies in cultures and in animals that suggests neurogenic and anti-tau activity, but this is a limited body of evidence, coming largely from related lines of work, and without clinical replication in humans. There are no consolidated clinical data on safety, pharmacokinetics, or dosing, nor regulatory approval for any use. Therefore, any interpretation of its results must be made with caution and within the strict framework of basic and preclinical research. For researchers, P21 represents an interesting tool for interrogating the CNTF-derived neurotrophic pathways, but its translational value remains to be established and its described effects should be independently verified before drawing firm conclusions.